The groundbreaking rise of Viagra has consistently remained a benchmark of pharmaceutical success, yet its position within the broader industry now raises questions about long-term returns . Copycat versions are diminishing exclusivity , leading to worries that investing in companies closely tied to Viagra's previous position could be a speculative